The Molecular Pathogenesis of the NUP98-HOXA9 Fusion Protein in Acute Myeloid Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 Jun 21

PMID 28630438

Citations 22

Authors

A Rio-Machin

G Gomez-Lopez

J Munoz

F Garcia-Martinez

A Maiques-Diaz

S Alvarez

R N Salgado

M Shrestha

R Torres-Ruiz

C Haferlach

M J Larrayoz

M J Calasanz

J Fitzgibbon

J C Cigudosa

Affiliations

Soon will be listed here.

Citing Articles

Biomolecular condensation of human IDRs initiates endogenous transcription via intrachromosomal looping or high-density promoter localization.

Li J, Liu S, Kim S, Goell J, Drum Z, Flores J Nucleic Acids Res. 2025; 53(4).

PMID: 39933697 PMC: 11811730. DOI: 10.1093/nar/gkaf056.

Prognostic importance of NUP98-rearrangements in acute myeloid leukemia: A systematic review and meta-analysis.

Sheikhi M, Siyadat P, Rostami M, Sadeghian M, Zahiri E, Ghorbani M Caspian J Intern Med. 2024; 15(4):579-588.

PMID: 39359452 PMC: 11444110. DOI: 10.22088/cjim.15.4.579.

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities.

Rasouli M, Troester S, Grebien F, Goemans B, Zwaan C, Heidenreich O Hemasphere. 2024; 8(9):e70013.

PMID: 39323480 PMC: 11423334. DOI: 10.1002/hem3.70013.

Clinical features and prognosis of patients with myeloid neoplasms harboring t(7;11)(p15;p15) translocation: a single-center retrospective study.

Liu L, Zhao S, Wang L, Xu H, Chen Z, Tu J BMC Cancer. 2024; 24(1):955.

PMID: 39103751 PMC: 11301825. DOI: 10.1186/s12885-024-12679-8.

A novel therapeutic strategy: the significance of exosomal miRNAs in acute myeloid leukemia.

Salehi A Med Oncol. 2024; 41(2):62.

PMID: 38253748 DOI: 10.1007/s12032-023-02286-1.

References

Baker A, Gregory G, Verbrugge I, Kats L, Hilton J, Vidacs E . The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Res. 2015; 76(5):1158-69. DOI: 10.1158/0008-5472.CAN-15-1070. View

Anne M, Sammartino D, Barginear M, Budman D . Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther. 2013; 6:1613-24. PMC: 3833618. DOI: 10.2147/OTT.S30773. View

Xu H, Valerio D, Eisold M, Sinha A, Koche R, Hu W . NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. Cancer Cell. 2016; 30(6):863-878. PMC: 5501282. DOI: 10.1016/j.ccell.2016.10.019. View

Takeda A, Goolsby C, Yaseen N . NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. Cancer Res. 2006; 66(13):6628-37. DOI: 10.1158/0008-5472.CAN-06-0458. View

Bots M, Verbrugge I, Martin B, Salmon J, Ghisi M, Baker A . Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood. 2014; 123(9):1341-52. PMC: 3938147. DOI: 10.1182/blood-2013-03-488114. View

San-Miguel J, Hungria V, Yoon S, Beksac M, Dimopoulos M, Elghandour A . Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014; 15(11):1195-206. DOI: 10.1016/S1470-2045(14)70440-1. View

Smith E, Shilatifard A . Enhancer biology and enhanceropathies. Nat Struct Mol Biol. 2014; 21(3):210-9. DOI: 10.1038/nsmb.2784. View

Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H . PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood. 2012; 121(8):1422-31. PMC: 3578957. DOI: 10.1182/blood-2012-07-442004. View

Deveau A, Forrester A, Coombs A, Wagner G, Grabher C, Chute I . Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98-HOXA9-induced myeloid disease. Leukemia. 2015; 29(10):2086-97. DOI: 10.1038/leu.2015.126. View

10.

Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa J, Wilhelm J . Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008; 13(6):483-95. PMC: 2486365. DOI: 10.1016/j.ccr.2008.04.020. View

11.

Moore M, Chung K, Plasilova M, Schuringa J, Shieh J, Zhou P . NUP98 dysregulation in myeloid leukemogenesis. Ann N Y Acad Sci. 2007; 1106:114-42. DOI: 10.1196/annals.1392.019. View

12.

Mulloy J, Cammenga J, Berguido F, Wu K, Zhou P, Comenzo R . Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 2003; 102(13):4369-76. DOI: 10.1182/blood-2003-05-1762. View

13.

Liang Y, Franks T, Marchetto M, Gage F, Hetzer M . Dynamic association of NUP98 with the human genome. PLoS Genet. 2013; 9(2):e1003308. PMC: 3585015. DOI: 10.1371/journal.pgen.1003308. View

14.

Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74. PMC: 3767041. DOI: 10.1056/NEJMoa1301689. View

15.

De Santa F, Barozzi I, Mietton F, Ghisletti S, Polletti S, Tusi B . A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol. 2010; 8(5):e1000384. PMC: 2867938. DOI: 10.1371/journal.pbio.1000384. View

16.

Garcia-Cuellar M, Steger J, Fuller E, Hetzner K, Slany R . Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia. Haematologica. 2015; 100(7):905-13. PMC: 4486225. DOI: 10.3324/haematol.2015.124032. View

17.

Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C . Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood. 2011; 119(2):388-98. PMC: 3257007. DOI: 10.1182/blood-2011-03-341081. View

18.

Oka M, Mura S, Yamada K, Sangel P, Hirata S, Maehara K . Chromatin-prebound Crm1 recruits Nup98-HoxA9 fusion to induce aberrant expression of Hox cluster genes. Elife. 2016; 5:e09540. PMC: 4718815. DOI: 10.7554/eLife.09540. View